[Epoetin in cancer treatment--the end of the game?].
作者信息
Wisløff Finn
出版信息
Tidsskr Nor Laegeforen. 2007 Sep 20;127(18):2359.
PMID:17895937
Abstract
摘要
相似文献
1
[Epoetin in cancer treatment--the end of the game?].
Tidsskr Nor Laegeforen. 2007 Sep 20;127(18):2359.
2
Report on epoetin use in oncology is precursor to guidelines.
Rep Med Guidel Outcomes Res. 2001 May 31;12(11):8-9.
3
Epoetin alfa: future directions and future research.
Oncologist. 2004;9 Suppl 5:70-3. doi: 10.1634/theoncologist.9-90005-70.
4
Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
J Clin Oncol. 2009 Dec 1;27(34):5751-6. doi: 10.1200/JCO.2009.22.3693. Epub 2009 Nov 2.
5
Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer.
Eur J Cancer. 2005 Dec;41(18):2789-91. doi: 10.1016/j.ejca.2005.07.021. Epub 2005 Oct 25.
6
Suboptimal hemoglobin levels: do they impact patients and their therapy? Introduction.
Semin Oncol. 2000 Apr;27(2 Suppl 4):1-3.
7
Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
Singapore Med J. 2009 Apr;50(4):365-70.
8
Optimal hemoglobin levels for cancer patients.
Semin Oncol. 2000 Apr;27(2 Suppl 4):12-5; discussion 16-7.
9
Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.
J Clin Oncol. 2009 Feb 1;27(4):644-6. doi: 10.1200/JCO.2008.20.4966. Epub 2008 Dec 22.
10
Anemia and response to epoetin alfa: the cause of anemia matters!
J Am Geriatr Soc. 2008 Aug;56(8):1574-5. doi: 10.1111/j.1532-5415.2008.01776.x.
Zotero 插件